Marinus Pharmaceuticals Inc

+0.02 (+0.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)325.01M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.55 Million
Adjusted EPS-$0.61
See more estimates
10-Day MA$6.26
50-Day MA$4.80
200-Day MA$5.51
See more pivots

Marinus Pharmaceuticals Inc Stock, NASDAQ:MRNS

5 Radnor Corporate Center, 100 Matsonford Road, Radnor, Pennsylvania 19087-5279
United States of America
Phone: +1.484.801.4670
Number of Employees: 113


Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.